Alzheimer’s and Parkinson’s are two diseases that have been considered as one of the most difficult in medical science for decades. The world has been dying to find answers, something that can help extend or even halt the course of these life-changing illnesses in families and patients.
The good news is that actual breakthroughs are being witnessed in the quest to find new Alzheimer’s medication and meaningful therapies to treat Parkinson’s dementia disease, as millions have been longing to see some form of change.
The Search for Effective Treatments
Alzheimer’s and Parkinson’s are both diseases that entail the progressive deterioration of nerve cells. Whereas Alzheimer’s is characterized by the primary impairment of memory and cognition, Parkinson’s is characterized by the impairment of movement and coordination. Although they differ, scientists have found that the two conditions are both related to one thing, which is the accumulation of toxic proteins that destroy brain cells with time.
This finding has inspired scientists to consider something other than symptom management. Rather, they are also addressing the biological activity underlying these conditions at a deep level. And that is where the new Alzheimer’s drug and Parkinson’s disease dementia research are getting on track to get long-term, root-cause therapy rather than temporary relief.
A New Direction in Neurodegenerative Research
A potential future work in this area is to work towards limiting neurotoxic stress proteins, the toxic substances that disrupt nerve communications in the brain. Overaccumulation of these proteins results in nerve blockage caused by the inflammation, blockage of nerve signals, and eventual death of neurons.
The new generation of treatments is supposed to protect the brain cells and to heal their communication channels. With this common biological process, researchers are hopeful of finding therapies that can benefit several disease conditions and thus allow both Alzheimer’s and Parkinson’s patients to have improved brain performance and life quality.
Buntanetap: A New Way to Tackle Neurodegenerative Disorders
Buntanetap (formerly known as Posiphen) is an exciting product in this area. It is a small-molecule drug with a unique mechanism of action. Instead of monoclonal antibody therapies designed to target one protein at a time, Buntanetap simultaneously inhibits multiple neurotoxic proteins. Specifically, Buntanetap interferes with amyloid precursor proteins (APP) and the peptides produced from them (Aβ), tau, αSYN, and TDP-43.
Studying the literature, it is known that neurotoxic proteins are involved in all neurodegenerative diseases. Thus, this multi-target approach is much more comprehensive in treating neurodegenerative diseases; there are additional sources of neurotoxicity beyond amyloid proteins. Additionally, it is likely that the oral availability of the drug will make it more patient-friendly.
Conclusion
Although further investigations and experimentation are being conducted, neurodegenerative disease discovery is currently a speeding process. Each of these milestones moves the medical community in the right direction towards the future, where such conditions can be controlled and, hopefully, avoided.
Annovis has a strong commitment to addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company’s innovative approach centers on blocking multiple neurotoxic proteins simultaneously, aiming to repair the function of the brain and improve the overall quality of life of individuals.
Annovis Bio is focused on the creation of breakthrough new Alzheimer’s medication and therapies in the areas of Parkinson’s dementia disease in its research.
